Navigation Links
Masimo Reports First Quarter 2011 Financial Results

IRVINE, Calif., May 3, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended April 2, 2011.

Masimo’s total revenue, including royalties, for the first quarter rose 14% to $113.0 million, compared to $98.8 million for the first quarter of 2010.  Masimo’s first quarter product revenue rose 18% to $101.6 million, compared to $85.9 million for the first quarter of 2010.  Revenue from Masimo rainbow products rose 39% to $7.4 million in the first quarter, compared to $5.3 million for the first quarter of 2010.  

Net income for the first quarter was $18.0 million, or $0.30 per diluted share, compared to reported net income of $26.7 million, or $0.44 per diluted share, in the first quarter of 2010 and compared to adjusted net income of $14.3 million, or $0.24 per diluted share, in the first quarter of 2010.  Adjusted earnings per share in the first quarter of 2010 excludes $0.20 per diluted share from the net of a $30.1 million one-time gain related to an antitrust lawsuit victory and offset by $10.9 million in one-time grants and marketing initiatives.  One-time grants in the first quarter of 2010 included a $10.3 million donation to establish the Masimo Foundation for Ethics, Innovation and Competition in Healthcare.During the first quarter, the company shipped approximately 43,100 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 16% compared to approximately 37,100 in the same prior year period.  Masimo estimates its worldwide installed base as of April 2, 2011 to be 890,000 units, up 18% from 757,000 units as of April 3, 2010.Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “We continue to experience increasing global demand for our breakthrough technologies as evidenced by our new highs in product revenue and driver shipments in the quarter.  We continue to pursue our mission to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications.̶As of April 2, 2011, cash, cash equivalents and short-term investments totaled $105.6 million, compared to $88.3 million as of January 1, 2011.Conference Call Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results.  The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers.  The reservation code for both dial-in numbers is 58223656.  After the live webcast, the call will be available on Masimo's website through June 3, 2011. In addition, a telephonic replay of the call will be available through May 17, 2011.  The replay dial-in numbers are (800) 642-1687 for domestic callers and +1 (706) 645-9291 for international callers. Please use reservation code 58223656.

About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®."  Additional information about Masimo and its products may be found at

Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about: our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies; and global demand for our technologies.  These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements.  These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), which you may obtain for free on the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise.  We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor Contact: Sheree Aronson

Media Contact: Dana BanksVice President, Investor Relations, Masimo Corporation

Manager, Public Relations, Masimo Corporation (949) 297-7043

(949) 297-7348

dbanks@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.

MASIMO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) April 2, 2011January 1, 2011ASSETSCurrent assetsCash and cash equivalents

$ 105,604$
88,305Accounts receivable, net of allowance for doubtful accounts

51,88649,694Royalties receivable


42,16345,028Prepaid expenses

4,8817,887Deferred tax assets

12,54112,555Other current assets

2,9402,136Total current assets

231,787217,605Deferred cost of goods sold

51,91847,184Property and equipment, net

15,24915,951Intangible assets, net

10,46210,497Deferred tax assets

12,57612,560Other assets

5,9966,438Total assets

$ 327,988$
310,235LIABILITIES AND EQUITYCurrent liabilitiesAccounts payable

$   17,791$
22,150Accrued compensation

14,25321,074Accrued liabilities

9,8699,832Income taxes payable

4,490722Deferred revenue

16,69416,369Current portion of capital lease obligations

4650Total current liabilities

63,14370,197Deferred revenue

1,3901,554Capital lease obligations, less current portion

110122Other liabilities

8,6698,323Total liabilities

73,31280,196EquityMasimo Corporation stockholders’ equity:Common stock

6059Treasury stock

(1,209)(1,209)Additional paid-in capital

228,796222,206Accumulated other comprehensive income

797925Retained earnings

23,6775,664Total Masimo Corporation stockholders’ equity

252,121227,645Noncontrolling interest

2,5552,394Total equity

254,676230,039Total liabilities and equity

$ 327,988$
310,235MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands, except per share amounts) Three Months EndedApril 2,April 3,20112010Revenue:Product


11,46512,899Total revenue

113,04298,765Cost of goods sold

36,21029,228Gross profit

76,83269,537Operating expenses:Selling, general and administrative

41,46849,311Research and development

9,9759,410Antitrust litigation proceeds

—(29,968)Total operating expenses

51,44328,753Operating income

25,38940,784Non-operating income (expense)

194(347)Income before provision for income taxes

25,58340,437Provision for income taxes

7,42914,273Net income including noncontrolling interests

18,15426,164Net (income) loss attributable to the noncontrolling interests

(141)546Net income attributable to Masimo Corporation

26,710Net income per share attributable to Masimo Corporation stockholders:Basic


.44Weighted average shares used in per share calculations:Basic


60,99160,464Cash dividend declared per share

2.00The following table presents details of the share-based compensation expense that is included in each functional line item in the condensed consolidated statements of income above (in thousands): Three Months EndedApril 2, April 3,20112010Cost of goods sold

93Selling, general and administrative

2,5152,077Research and development


2,818MASIMO CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in thousands) Three Months EndedApril 2, 2011April 3, 2010Cash flows from operating activities:Net income including noncontrolling interests

$   18,154$   26,164Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:Depreciation and amortization

2,0441,577Share-based compensation

3,4332,818Provision for doubtful accounts

72233Provision for obsolete inventory

376249Provision for warranty costs

699619Income tax benefit from exercise of stock options granted prior to January 1, 2006

751555Excess tax deficit (benefit) from share-based payment arrangements

198(1,383)Changes in operating assets and liabilities:Increase in accounts receivable

(2,263)(7,375)(Increase) decrease in royalties receivable

228(500)(Increase) decrease in inventories

2,489(2,388)Increase in deferred cost of goods sold

(4,673)(1,902)Decrease in prepaid expenses

3,0281,375Increase in other assets

(356)(1,013)Increase (decrease) in accounts payable

(4,375)4,256Decrease in accrued compensation

(6,981)(2,646)Decrease in accrued liabilities

(721)(724)Increase in income taxes payable

3,55511,401Increase in deferred revenue

1614,429Increase in other liabilities

361313Net cash provided by operating activities

16,18036,058Cash flows from investing activities:Purchase of short-term investments

—(75,986)Proceeds from sale and maturities of short-term investments

—56,989Purchases of property and equipment

(808)(1,885)Increase in intangible assets

(498)(264)Net cash used in investing activities

(1,306)(21,146)Cash flows from financing activities:Repayments of capital lease obligations

(16)(15)Proceeds from issuance of common stock

2,6285,354Excess tax (deficit) benefit from share-based payment arrangements

(198)1,383Dividends paid

—(117,506)Net cash provided by (used in) financing activities

2,414(110,784)Effect of foreign currency exchange rates on cash

11(29)Net increase (decrease) in cash and cash equivalents

17,299(95,901)Cash and cash equivalents at beginning of period

88,305132,054Cash and cash equivalents at end of period

$ 105,604$   36,153

SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
2. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
3. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
4. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
5. Masimo to Report Third Quarter 2009 Financial Results on November 3, 2009
6. New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology
7. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
8. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
9. St.Vincent Hospital Renews Multi-Year, System-wide Contract for Masimo SET(R) Pulse Oximetry Technology
10. Masimo Expands its Irvine, California Corporate Headquarters to Accommodate Growth Projections
11. Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
Breaking Medicine News(10 mins):